Trends in the treatment of anemia using recombinant human erythropoietin in patients with HIV infection.

The authors analyze trends in utilization of rHuEPO therapy in patients with HIV infection. Two databases underwent analysis and the authors report that significant numbers, ranging from 18% to 56% of outpatients with HIV infection, are maintained at Hb targets ≥12 g/dL. The authors propose that Hgb level treatment goals be reassessed in light of recent FDA modifications in use of rHuEPO therapy.

– Lawrence Tim Goodnough